G2/M-Phase-Inhibitory Mitochondrial-Depolarizing Re(I)/Ru(II)/Ir(III)-2,2′-Bipyrimidine-Based Heterobimetallic Luminescent Complexes: An Assessment of In Vitro Antiproliferative Activity and Bioimaging for Targeted Therapy toward Human TNBC Cells

Triple-negative breast cancer (TNBC) is an extremely vicious subtype of human breast cancer having the worst prognosis along with strong invasive and metastatic competency. Hence, it can easily invade into blood vessels, and presently, no targeted therapeutic approach is available to annihilate this type of cancer. Metal complexes have successfully stepped into the anticancer research and are now being applauded due to their anticancer potency after the discovery of cisplatin. Many of these metal complexes are also well recognized for their activity toward breast cancer. As the TNBC is a very dangerous subtype and has long been a challenging ailment to treat, we have intended to develop a few brand new mixed metallic Ru(II)/Ir(III)/Re(I)-2,2′-bipyrimidine complexes [L′Re2], [L′RuRe], and [L′IrRe] to abate the unbridled proliferation of TNBC cells. The potency of the complexes against TNBC cells has been justified using MDA-MB-468 TNBC cell lines where complex [L′IrRe] has displayed significant potency among all the three complexes with an IC50 value of 24.12 μM. The complex [L′IrRe] has been competent to cause apoptosis of TNBC cells through inhibition of the G2/M phase in the cell cycle in association with a profuse amount of ROS generation and mitochondrial depolarization.

[1]  R. Eswaramoorthy,et al.  Metal Complexes in Target-Specific Anticancer Therapy: Recent Trends and Challenges , 2022, Journal of Chemistry.

[2]  P. Paira,et al.  Mitochondria-targeted half-sandwich iridium(iii)-Cp*-arylimidazophenanthroline complexes as antiproliferative and bioimaging agents against triple negative breast cancer cells MDA-MB-468 , 2022, RSC advances.

[3]  B. Han,et al.  Targeting regulated cell death (RCD) with small-molecule compounds in triple-negative breast cancer: a revisited perspective from molecular mechanisms to targeted therapies , 2022, Journal of Hematology & Oncology.

[4]  H. Rugo,et al.  Immunotherapy for early triple negative breast cancer: research agenda for the next decade , 2022, NPJ breast cancer.

[5]  A. Atoui,et al.  Clinical Significance of Breast Cancer Molecular Subtypes and Ki67 Expression as a Predictive Value for Pathological Complete Response following Neoadjuvant Chemotherapy: Experience from a Tertiary Care Center in Lebanon , 2022, International journal of breast cancer.

[6]  M. Cominetti,et al.  Ruthenium(II)-diphosphine complexes containing acylthiourea ligands are effective against lung and breast cancers. , 2022, Dalton transactions.

[7]  F. Zobi,et al.  Anticancer and Antibiotic Rhenium Tri- and Dicarbonyl Complexes: Current Research and Future Perspectives , 2022, Molecules.

[8]  Tianfeng Chen,et al.  Ruthenium complexes boost NK cell immunotherapy via sensitizing triple-negative breast cancer and shaping immuno-microenvironment. , 2022, Biomaterials.

[9]  Z. Mao,et al.  Ferroptosis-Enhanced Cancer Immunity by a Ferrocene-Appended Iridium(III) Diphosphine Complex. , 2021, Angewandte Chemie.

[10]  Qianling Zhang,et al.  Metal complexes against breast cancer stem cells. , 2021, Dalton transactions.

[11]  P. Paira,et al.  2,2'-Bipyrimidine-based luminescent Ru(ii)/Ir(iii)-arene monometallic and homo- and hetero-bimetallic complexes for therapy against MDA-MB-468 and caco-2 cells. , 2021, Dalton transactions.

[12]  Tripti Sharma,et al.  Pyrimidine: a review on anticancer activity with key emphasis on SAR , 2021, Future Journal of Pharmaceutical Sciences.

[13]  M. Contel,et al.  Exploring the Potential of Metallodrugs as Chemotherapeutics for Triple Negative Breast Cancer. , 2021, Chemistry.

[14]  Aneta Cieśla-Niechwiadowicz,et al.  Novel Pyrimidine Derivatives as Potential Anticancer Agents: Synthesis, Biological Evaluation and Molecular Docking Study , 2021, International journal of molecular sciences.

[15]  Qianling Zhang,et al.  Sulfur‐Coordinated Organoiridium(III) Complexes Exert Breast Anticancer Activity via Inhibition of Wnt/β‐Catenin Signaling , 2021, Angewandte Chemie.

[16]  L. Di,et al.  Cisplatin prevents breast cancer metastasis through blocking early EMT and retards cancer growth together with paclitaxel , 2021, Theranostics.

[17]  Liang He,et al.  Dinuclear phosphorescent rhenium(i) complexes as potential anticancer and photodynamic therapy agents. , 2020, Dalton transactions.

[18]  S. Loibl,et al.  Optimal Systemic Treatment for Early Triple-Negative Breast Cancer. , 2020, Breast care.

[19]  V. Rotello,et al.  Triple-Negative Breast Cancer: A Review of Conventional and Advanced Therapeutic Strategies , 2020, International journal of environmental research and public health.

[20]  A. Castonguay,et al.  Rationally Designed Ruthenium Complexes for Breast Cancer Therapy , 2020, Molecules.

[21]  Elyse Watkins.  Overview of breast cancer. , 2019, JAAPA : official journal of the American Academy of Physician Assistants.

[22]  Robert M. Reich,et al.  Organometallic and coordination rhenium compounds and their potential in cancer therapy , 2019, Coordination Chemistry Reviews.

[23]  C. Leung,et al.  Iridium(III) Complexes Targeting Apoptotic Cell Death in Cancer Cells , 2019, Molecules.

[24]  Chilaluck C. Konkankit,et al.  In Vivo Anticancer Activity of a Rhenium(I) Tricarbonyl Complex. , 2019, ACS medicinal chemistry letters.

[25]  A. Isab,et al.  Potent In Vitro and In Vivo Anticancer Activity of New Bipyridine and Bipyrimidine Gold (III) Dithiocarbamate Derivatives , 2019, Cancers.

[26]  N. Doucet,et al.  Organoruthenium(II) Complexes Bearing an Aromatase Inhibitor: Synthesis, Characterization, in Vitro Biological Activity and in Vivo Toxicity in Zebrafish Embryos. , 2019, Organometallics.

[27]  M. Freire-Garabal,et al.  Non-Platinum Metal Complexes as Potential Anti-Triple Negative Breast Cancer Agents , 2018, Crystals.

[28]  B. Narasimhan,et al.  Therapeutic potential of heterocyclic pyrimidine scaffolds , 2018, Chemistry Central Journal.

[29]  Justin J. Wilson,et al.  In Vitro Anticancer Activity and in Vivo Biodistribution of Rhenium(I) Tricarbonyl Aqua Complexes. , 2017, Journal of the American Chemical Society.

[30]  J. Ellena,et al.  Cytotoxicity and anti-tumor effects of new ruthenium complexes on triple negative breast cancer cells , 2017, PloS one.

[31]  S. Pakhomova,et al.  Synthesis, Characterization, and Biological Studies of a Piperidinyl Appended Dipicolylamine Ligand and Its Rhenium Tricarbonyl Complex as Potential Therapeutic Agents for Human Breast Cancer , 2016, Bioinorganic chemistry and applications.

[32]  S. Radulović,et al.  Synthesis, characterization and biological evaluation of novel Ru(II)-arene complexes containing intercalating ligands. , 2016, Journal of inorganic biochemistry.

[33]  H. Salehiniya,et al.  Incidence and Mortality and Epidemiology of Breast Cancer in the World. , 2016, Asian Pacific journal of cancer prevention : APJCP.

[34]  C. Shriver,et al.  Inhibition of cancer cell growth by ruthenium complexes , 2016, Journal of Translational Medicine.

[35]  F. Shirini,et al.  Synthesis of benzimidazole and quinoxaline derivatives using reusable sulfonated rice husk ash (RHA-SO3H) as a green and efficient solid acid catalyst , 2016, Research on Chemical Intermediates.

[36]  Youjun Wang,et al.  DNA Binding and Photocleavage Properties, Cellular Uptake and Localization, and in-Vitro Cytotoxicity of Dinuclear Ruthenium(II) Complexes with Varying Lengths in Bridging Alkyl Linkers. , 2016, Inorganic chemistry.

[37]  Hannah U. Holtkamp,et al.  Impact of the Halogen Substitution Pattern on the Biological Activity of Organoruthenium 8-Hydroxyquinoline Anticancer Agents , 2015 .

[38]  A. Patra,et al.  Luminescent europium and terbium complexes of dipyridoquinoxaline and dipyridophenazine ligands as photosensitizing antennae: structures and biological perspectives. , 2015, Dalton transactions.

[39]  J. Lortet-Tieulent,et al.  Breast Cancer Screening for Women at Average Risk: 2015 Guideline Update From the American Cancer Society. , 2015, JAMA.

[40]  Anil H. Gore,et al.  Spectroscopic analysis on the binding interaction of biologically active pyrimidine derivative with bovine serum albumin☆ , 2015, Journal of pharmaceutical analysis.

[41]  Saqib Ali,et al.  Drug-DNA interactions and their study by UV-Visible, fluorescence spectroscopies and cyclic voltametry. , 2013, Journal of photochemistry and photobiology. B, Biology.

[42]  P. Sadler,et al.  Organometallic Iridium(III) Anticancer Complexes with New Mechanisms of Action: NCI-60 Screening, Mitochondrial Targeting, and Apoptosis , 2013, ACS chemical biology.

[43]  A. Samanta,et al.  Diffusion of organic dyes in bovine serum albumin solution studied by fluorescence correlation spectroscopy , 2012 .

[44]  David S. Goodsell,et al.  AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility , 2009, J. Comput. Chem..

[45]  J. Keizer.  Additions and Corrections - Nonlinear Fluorescence Quenching and the Origin of Positive Curvature in Stern-Volmer Plots , 1983 .